PMID- 26682290
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20220331
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 96
IP  - 4
DP  - 2015 Oct
TI  - Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts 
      in men.
PG  - 277-82
AB  - We assess the safety and efficacy of imiquimod cream 3.75% and 2.5% in men with 
      external genital warts (EGWs). Two multicenter, randomized, double-blind, 
      placebo-controlled studies were conducted in a total of 447 (225 from study 1 and 
      222 from study 2) male patients (aged >/=12 years) with 2 to 30 EGWs and a total 
      wart area of 150 mm2 or greater. Participants were randomized (2:2:1) to 
      imiquimod cream 3.75% or 2.5% or placebo applied once daily until complete 
      clearance or a maximum of 8 weeks (end of treatment [EOT]). There was an 8-week 
      follow-up period (end of study [EOS]) for participants who did not achieve 
      complete clearance by EOT. Participants who achieved complete clearance were 
      observed for an additional 12 weeks. The primary efficacy end point was complete 
      clearance rate. Safety assessments included visual assessment of local skin 
      reactions, number and duration of required rest periods, adverse events (AEs), 
      and clinical laboratory tests. Study results indicated that new imiquimod 
      formulations are beneficial in treating EGWs in men.
FAU - Rosen, Ted
AU  - Rosen T
AD  - Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA.
FAU - Nelson, Anita
AU  - Nelson A
AD  - Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, 
      California, USA.
FAU - Ault, Kevin
AU  - Ault K
AD  - Department of Gynecology and Obstetrics, Emory University School of Medicine, 
      Atlanta, Georgia, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Aminoquinolines)
RN  - P1QW714R7M (Imiquimod)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage/adverse effects
MH  - Adult
MH  - Aminoquinolines/*administration & dosage/adverse effects
MH  - Condylomata Acuminata/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - Imiquimod
MH  - Male
MH  - Treatment Outcome
EDAT- 2015/12/19 06:00
MHDA- 2016/10/08 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
AID - NJ_0C00306E [pii]
PST - ppublish
SO  - Cutis. 2015 Oct;96(4):277-82.